You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
In an analyst briefing, Pfizer described plans to advance several precision oncology assets in earlier disease settings and in combination with other therapies.
The partners are hoping to leverage their expertise to advance drugs with a novel mechanism of action that will target a broader range of RAS mutations.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
The partners will develop technology to predict the outcome of an NK-cell-based immunotherapy in patients with incurable locally advanced or metastatic solid tumors.